These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28545714)

  • 1. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
    Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
    Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
    Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
    Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the vulnerability to NAD
    Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
    Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
    Cordover E; Wei J; Patel C; Shan NL; Gionco J; Sargsyan D; Wu R; Cai L; Kong AN; Jacinto E; Minden A
    Chem Res Toxicol; 2020 Feb; 33(2):482-491. PubMed ID: 31876149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
    Rane C; Senapedis W; Baloglu E; Landesman Y; Crochiere M; Das-Gupta S; Minden A
    Sci Rep; 2017 Feb; 7():42555. PubMed ID: 28198380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
    Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
    Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
    Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
    Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
    de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
    Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAZ/Wnt-β-catenin/c-MYC axis regulates cystogenesis in polycystic kidney disease.
    Lee EJ; Seo E; Kim JW; Nam SA; Lee JY; Jun J; Oh S; Park M; Jho EH; Yoo KH; Park JH; Kim YK
    Proc Natl Acad Sci U S A; 2020 Nov; 117(46):29001-29012. PubMed ID: 33122431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
    Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
    Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD.
    Li A; Xu Y; Fan S; Meng J; Shen X; Xiao Q; Li Y; Zhang L; Zhang X; Wu G; Liang C; Wu D
    JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.
    Leonhard WN; van der Wal A; Novalic Z; Kunnen SJ; Gansevoort RT; Breuning MH; de Heer E; Peters DJ
    Am J Physiol Renal Physiol; 2011 May; 300(5):F1193-202. PubMed ID: 21345977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels.
    Tan M; Wettersten HI; Chu K; Huso DL; Watnick T; Friedlander S; Landesman Y; Weiss RH
    Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1179-86. PubMed ID: 25234309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.
    Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G
    Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
    Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT; Landesman Y; Wagner KU; Viola NT; El-Rayes BF; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2021 Oct; 20(10):1836-1845. PubMed ID: 34253597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
    Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
    J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
    Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
    J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease.
    Wang X; Jiang L; Thao K; Sussman CR; LaBranche T; Palmer M; Harris PC; McKnight GS; Hoeflich KP; Schalm S; Torres VE
    J Am Soc Nephrol; 2022 Jun; 33(6):1087-1104. PubMed ID: 35236775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.
    Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC
    Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
    Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
    Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.